Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 40Lymphoma 39Melanoma 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Breast Neoplasms 21Lymphoma, Large B-Cell, Diffuse 20Lymphoma, Mantle-Cell 19Myelodysplastic Syndromes 17Neuroblastoma 16Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Multiple Myeloma 15Leukemia, Myeloid, Chronic-Phase 15Leukemia, Myeloid, Acute 15Burkitt Lymphoma 15Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Prostatic Neoplasms 13Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Neoplasms, Plasma Cell 10Leukemia, Myeloid, Accelerated Phase 10Glioblastoma 10Congenital Abnormalities 10Carcinoma, Ovarian Epithelial 9Ovarian Neoplasms 8

Interventions

sargramostim 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Transplant-Related Hematologic Malignancy × sargramostim × Clear all
NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Northside Hospital, Inc.

Phase 2 Recruiting
38 enrolled

Transplant-Related Hematologic Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡